Further Evidence That Hrt Does Not Protect Against Cardiovascular Disease (p 2001)December 18, 2002Results of a UK randomised trial published in this week's issue of THE LANCET provides further evidence that hormone replacement therapy (HRT) does not offer women protection against cardiovascular disease. Previous observational studies have suggested that HRT could reduce the risk of coronary heart disease (CHD), but results of randomised trials do not suggest a lower risk in women who use combination oestrogen/progestagen therapy. A team of scientists from the University of Manchester, UK, assessed whether or not oestrogen reduced the risk of further cardiac events in postmenopausal women who survived a first heart attack. Around 1000 postmenopausal women, age 50-69 years who had survived a first heart attack were recruited from 35 hospitals in England and Wales. They were given either one daily tablet of 2 mg oestradiol valerate or placebo for two years. There was no difference in the frequency of recurrent heart attack or cardiac death at follow-up, and the difference in all-cause mortality (lower among women given oestrogen therapy) was not statistically significant. Nicola Cherry, the principal investigator, comments: "Oestrogen therapy does not reduce the overall risk of further cardiac events in postmenopausal women who have survived aheart attack. This study provides insufficient evidence of benefit to alter current guidance against the use of HRT for the secondary prevention of cardiovascular disease." See also Commentary - 'Hormones for coronary disease-full circle' (p 1996). Lancet |
|||||||||||||||||||||
| Related Estrogen Current Events and Estrogen News Articles Heart and bone damage from low vitamin D tied to declines in sex hormones Researchers at Johns Hopkins are reporting what is believed to be the first conclusive evidence in men that the long-term ill effects of vitamin D deficiency are amplified by lower levels of the key sex hormone estrogen, but not testosterone. Fertility procedures need not delay breast cancer treatment for younger women A new study published in the November issue of the Journal of the American College of Surgeons shows that breast cancer patients under 40 years old who undergo fertility preservation do not face a significant delay in the treatment of their disease when their care is coordinated in a timely fashion. Coffee break: Compound brewing new research in colon, breast cancer A compound in coffee has been found to be estrogenic in studies by Texas AgriLife Research scientists. Mayo researchers find robotic repair for vaginal prolapse has significant benefits New Mayo Clinic research has found that robotic surgery for vaginal prolapse dramatically reduces patient hospital stay and recovery time. Estrogen therapy likely must be given soon after menopause to provide stroke protection For estrogen replacement to provide stroke protection, it likely must be given soon after levels drop because of menopause or surgical removal of the ovaries, scientists report in the Journal of Neuroscience. Oral contraceptives may benefit women with asthma New research shows that during natural menstrual cycles, women with asthma who were not taking oral contraceptives (OC) had lower exhaled nitric oxide levels (eNO), a marker of airway inflammation associated with asthma, than women who were taking OC. Study shows hormone replacement therapy decreases mortality in younger postmenopausal woman Hormone replacement therapy (HRT) to treat menopausal estrogen deficiency has been in widespread use for over 60 years. Several observational studies over the years showed that HRT use by younger postmenopausal women was associated with a significant reduction in total mortality; available evidence supported the routine use of HRT to increase longevity in postmenopausal women. Hormone mix could cut breast cancer risk and treat symptoms of menopause The right combination of estrogen and a selective estrogen receptor modulator (SERM), which blocks the effects of estrogen in breast tissue, could relieve menopause symptoms and cut breast cancer risk. Breast tenderness during hormone replacement therapy linked to elevated cancer risk Women who developed new-onset breast tenderness after starting estrogen plus progestin hormone replacement therapy were at significantly higher risk for developing breast cancer than women on the combination therapy who didn't experience such tenderness, according to a new UCLA study. Study finds no relationship between PCR rate and race in women with breast cancer Locally advanced breast cancer patients who received the same class of neoadjuvant chemotherapy were found to have no evidence of disease at the time of their surgery, or achieved pathological complete response, at the same rate regardless of race, according to researchers at The University of Texas M. D. Anderson Cancer Center. More Estrogen Current Events and Estrogen News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||